RDN for CKD and Uncontrolled Hypertension Trial
Effect and Safety of Renal Denervation in Uncontrolled Hypertension and Chronic Kidney Disease: A Randomized, Sham-control, Blinded, Clinical Trial
Prospective, Multi-Center, Randomized, Parallel-Controlled, Uptake clinical trial to evaluate the efficacy and safety of renal denervation in patients with uncontrolled hypertension and chronic kidney disease.
研究概览
详细说明
This Prospective, Multi-Center, Randomized, parallel-controlled uptake clinical trial aims to evaluate the efficacy and safety for renal denervation in patients with uncontrolled hypertension and chronic kidney disease, and to provide clinical evidence supporting the expansion of indications.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Luyun Fan
- 电话号码:+86-13522601484
- 邮箱:katevan@163.com
研究联系人备份
- 姓名:Jingjing Zhou
- 电话号码:+86-18742568090
- 邮箱:zhoujjrf0901@163.com
学习地点
-
-
-
Beijing、中国、101118
- 招聘中
- Beijing Anzhen Hospital
-
接触:
- Jun Cai
- 电话号码:+86-13810615602
- 邮箱:caijun7879@126.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Male or female, aged 18 to 65 years, inclusive, at the time of consent;
- Hypertensive subjects who have been taking 2 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure still ≥150 mmHg and <180 mmHg, and 24-hour ambulatory mean systolic blood pressure (24h SBP) ≥135 mmHg and <170 mmHg; or who have been taking ≥3 types of standardized antihypertensive drugs continuously and stably for at least 4 weeks, with office systolic blood pressure ≥140 mmHg and <180 mmHg, and 24h SBP ≥130 mmHg and <170 mmHg;
- Estimated glomerular filtration rate (eGFR) ≥20 mL/min/1.73m² and <60 mL/min/1.73m²;
- The presence or absence of accessory renal arteries is acceptable;
- The subject or his/her legal representative fully understands the content of the informed consent form for this trial and voluntarily signs the written informed consent form.
Exclusion Criteria:
- Pregnant or breastfeeding, or planning pregnancy during the study.
- Renal artery anatomy unsuitable for ablation (e.g., ≥50% stenosis, renal artery aneurysm, malformation, renal artery diameter <3 mm, or treatable segment length <20 mm).
- Subjects with a solitary kidney, prior renal transplantation, or requiring dialysis.
- Prior renal artery intervention or prior renal denervation.
- Other secondary hypertension not related to kidney disease (such as primary aldosteronism, pheochromocytoma/paraganglioma, Cushing's syndrome, thyroid disease, aortic coarctation, monogenic hypertension, renovascular hypertension, etc.).
- Allergic to contrast agents.
- Major surgery or trauma within 1 month before enrollment; acute coronary syndrome within 6 months; or planned surgery or cardiovascular interventional therapy within the next 6 months.
- Orthostatic hypotension.
- Type 1 diabetes mellitus.
- Primary pulmonary arterial hypertension.
- History of bleeding diathesis and haematological disorders or coagulopathy
- History of thromboembolic event within 6 months.
- History of stroke or transient ischemic attack (TIA) within 6 months.
- Severe peripheral arterial disease or unstable abdominal aortic aneurysm.
- Severe valvular heart disease or anticipated need for surgical valve replacement during the study period.
- NYHA Class III/IV heart failure at screening or hospitalization for exacerbation of chronic heart failure within the past six months.
- History of ventricular fibrillation, polymorphic ventricular tachycardia within six months, or prior implantation of an implantable cardioverter-defibrillator (ICD) or pacemaker.
- Acute kidney injury (AKI) within 4 weeks before enrollment or acute kidney disease ,AKI: ≥50% increase in serum creatinine within 7 days, or absolute increase ≥0.3 mg/dL (≥26.5 μmol/L) within 48 hours, or oliguria (<0.5 mL·kg-¹·h-¹ for ≥6 hours).
- Severe hepatic dysfunction.
- Concomitant severe diseases that may interfere with study participation or affect survival, such as malignancy or AIDS.
- Known drug or alcohol dependence, difficulty understanding the study protocol, inability or unwillingness to comply with follow-up requirements.
- Current or planned participation in other clinical trials of drugs or medical devices (post-marketing registry studies permitted).
- Acute or severe systemic infection.
- Other conditions deemed unsuitable for participation by the investigator.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Renal Denervation (RDN)
Participants receive percutaneous renal sympathetic denervation under digital subtraction angiography (DSA) guidance using a ultra-guiding radiofrequency denervation catheter. All participants receive a standardized antihypertensive regimen for ≥4 weeks before the procedure and thereafter per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, 12 months. |
DSA-guided percutaneous renal sympathetic denervation using a RF renal denervation system
其他名称:
|
|
假比较器:Parallel control with sham operation
Participants undergo a sham procedure: femoral artery puncture and selective renal angiography under DSA guidance are performed. The RF generator is connected to a dummy load, and activation sounds are emitted, but no energy is delivered. Participants remain on the procedure table for at least 35 minutes before sheath removal. Background standardized antihypertensive therapy is provided for ≥4 weeks pre-procedure and continued per protocol. Follow-up visits occur at 7 days or before discharge, and at 1, 3, 6, and 12 months. |
Sham procedure including femoral artery puncture and selective renal angiography; the radiofrequency generator is connected to a dummy load and produces activation sounds, but no energy is delivered. Minimum table time before sheath removal is 35 minutes.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure at Month 6 (ABPM)
大体时间:Baseline to Month 6 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring; change is Month 6 minus Baseline |
Baseline to Month 6 post-procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change from Baseline in 24-hour Ambulatory Diastolic Blood Pressure at Month 6 (ABPM)
大体时间:Baseline to Month 6 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Baseline to Month 6 post-procedure
|
|
Change from Baseline in Office Blood Pressure (including both systolic and diastolic BP)
大体时间:Baseline to Months 1, 3, 6 and 12 post-procedure
|
measured by validated office blood pressure monitoring |
Baseline to Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in 24-hour Ambulatory Systolic Blood Pressure (including both systolic and diastolic BP)
大体时间:Baseline to Months 1, 3, and 12 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Baseline to Months 1, 3, and 12 post-procedure
|
|
Change from Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure (ABPM)
大体时间:Baseline to Months 1, 3, 6, and 12 post-procedure
|
24-hour mean systolic BP measured in Daytime and Nighttime by validated ambulatory BP monitoring |
Baseline to Months 1, 3, 6, and 12 post-procedure
|
|
Percentage of Participants with 24-hour Ambulatory Systolic BP <130 mmHg
大体时间:Months 1, 3, 6, and 12 post-procedure
|
24-hour mean systolic BP measured by validated ambulatory BP monitoring |
Months 1, 3, 6, and 12 post-procedure
|
|
Percentage of subjects with office systolic BP within the target ranges (<140 mmHg and <130 mmHg)
大体时间:Months 6 and 12 post-procedure
|
measured by validated office blood pressure monitoring |
Months 6 and 12 post-procedure
|
|
Responder Rate: ≥5 mmHg Reduction in office Systolic BP
大体时间:Months 6 and 12 post-procedure
|
Proportion of participants with a reduction ≥5 mmHg from baseline in office BP |
Months 6 and 12 post-procedure
|
|
Change from Baseline in Antihypertensive Medication Use
大体时间:Months 1, 3, 6 and 12 post-procedure
|
Change in the number of concurrently prescribed antihypertensive agents |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in serum creatinine levels
大体时间:Months 1, 3, 6 and 12 post-procedure
|
Change in postoperative serum creatinine levels relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Changes from Baseline in glomerular filtration rate
大体时间:Months 1, 3, 6 and 12 post-procedure
|
Changes in glomerular filtration rate relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Changes from Baseline in the urine microalbumin-to-creatinine ratio
大体时间:Months 1, 3, 6 and 12 post-procedure
|
Changes in the urine microalbumin-to-creatinine ratio relative to baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in Heart Rate (by ECG)
大体时间:Months 1, 3, 6 and 12 post-procedure
|
Resting heart rate measured by standard 12-lead ECG; change is Follow-up minus Baseline |
Months 1, 3, 6 and 12 post-procedure
|
|
Change from Baseline in left ventricular ejection fraction (LVEF) (by Echocardiography)
大体时间:Months 12 post-procedure
|
by Echocardiography |
Months 12 post-procedure
|
|
Change from Baseline in left ventricular mass index
大体时间:Months 12 post-procedure
|
by Echocardiography |
Months 12 post-procedure
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- BRWEP2024W012060105
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.